NPC1
Phase 2Small molecule
NPC1 is one of 50 small molecule programs targeting Alzheimer disease. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
91 competitors in Alzheimer Disease
#DrugCompanyPhaseTrials
1Kisunla
Eli LillyApproved
Leqembi
EisaiApproved
Dayvigo
EisaiApproved
Keppra
UCBApproved
Farxiga
AstraZenecaApproved
Cialis
Eli LillyApproved
Rifadin
SanofiApproved
Epidiolex
Jazz PharmaceuticalsApproved
Aleve
Jazz PharmaceuticalsApproved
Estrace
Novo NordiskApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NPC1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMassachusetts General Hospital